Following a joint venture in 2016, Bayer has now agreed to fully acquire biotech company BlueRock Therapeutics in a deal that values the company at $1 billion. According to Bayer’s press release, “Bayer will own full rights to BlueRock Therapeutics’ CELL+GENE™ platform, including a broad intellectual property portfolio and associated technology platform including proprietary iPSC technology...” The BlueRock Therapeutics’ portfolio of cell therapies targets diseases such as Parkinson’s.

Goodwin Procter advised BlueRock Therapeutics while Bayer was advised by Orrick Herrington & Sutcliffe. The notable transactional lawyers in the Goodwin team are Sarah A Solomon and Noelle Dubiansky, both of whom are partners who specialise in IP transactions in the life sciences sector. A notable lawyer in Orrick’s team is Mark Seneca, who specialises in advising high-tech companies.